Exploring Manufacturing Process Validation - BioTechLogic, Inc. is a biopharmaceutical manufacturing and CMC consulting firm with strategic and practical/hands-on experience that helps clients bring their products to market quickly and successfully by augmenting and optimizing an organization’s technical, manufacturing, analytical, and regulatory resources.
Our technical expertise resides in a wide range of biological and oligonucleotide products including recombinant proteins, vaccines and blood products. Through the combined expertise and knowledge of our staff, we have developed proven methodologies and approaches for providing reliable and dependable services in the following areas:
Process Development and Quality by Design (QbD) including:
Design of Experiments (DOE)
Development Reports
Critical Process Parameter Evaluation
Technology Implementation, Transfer and Scale-up
On-site third party contract manufacturing support
BioAnalytical Services
Process Validation
Biotechnology Project Management
Quality Assurance
Regulatory Submissions
PAI Inspection Readiness (FDA Pre-Approval Inspection Readiness)
In this presentation from CPhi 2014, Elise Gallais outlines the guidelines for cleaning validation: and focuses on analytical methods and their validation.
In this presentation from IVT's 4th Annual Validation Week EU, Paul Pluta, discussed the differences between the traditional approach to cleaning validation and the lifecycle approach, applicable regulatory guidance, current industry trends, the necessary phases of the lifecycle approach (design and definition, cycle development, validation, and implementation), how to continously monitor the process, change control, and common obstacles to compliance.
According to U.S.Food and Drug Administration
Process validation is establishing documented evidence which provides a high degree of assurance that a specific process will consistently produce a product meeting its predetermined specifications and quality characteristics.
In this presentation from CPhi 2014, Elise Gallais outlines the guidelines for cleaning validation: and focuses on analytical methods and their validation.
In this presentation from IVT's 4th Annual Validation Week EU, Paul Pluta, discussed the differences between the traditional approach to cleaning validation and the lifecycle approach, applicable regulatory guidance, current industry trends, the necessary phases of the lifecycle approach (design and definition, cycle development, validation, and implementation), how to continously monitor the process, change control, and common obstacles to compliance.
According to U.S.Food and Drug Administration
Process validation is establishing documented evidence which provides a high degree of assurance that a specific process will consistently produce a product meeting its predetermined specifications and quality characteristics.
In the last year or so the FDA and the EMA have issued new guidance/ draft guidance on "Process Validation".These align process validation activities with a product lifecycle concept and the International Conference on Harmonisation (ICH) guidances for industry, Q8(R2) Pharmaceutical Development, Q9 Quality Risk Management, and Q10 Pharmaceutical Quality System. The earlier guidelines were developed before the elaboration of the new ICH guidelines.With these new guidelines, additional opportunities are available to verify the control of the process by alternative means to the manufacture of traditional process validation batches. The main objective of process validation remains that a process design yields a product meeting its pre-defined quality criteria. ICH Q8, Q9 and Q10 provide a structured way to define product critical quality attributes, design space, the manufacturing process and the control strategy. ICH Q8 refers to an ‘enhanced’ approach to pharmaceutical development which includes an alternative to the traditional process validation.
Continuous process verification [see definition in ICH Q8(R2) glossary] can be utilised in process validation protocols for the initial commercial production and for manufacturing process changes for the continual improvement throughout the remainder of the product lifecycle.
There is now a new paradigm in process validation. This presentation has been prepared from material available from FDA , EMA and ICH for beginners to have an overview of the new paradigm.
Cleaning validation is one of the major and critical activity in pharmaceutical operations
The four basic requirement of cGmp are …
Identity
Safety*
Strength
Purity*
This presentation covers the manufacture and testing of all sterile drug products, including drugs that are sterilized by filtration or other means and aseptically processed, and drug products that are terminally sterilized. The type of products covered include sterile bulk drugs, ophthalmic drugs, otic dosage forms, small volume parenteral (SVS) products for small molecule and licensed biological
therapeutic drug products, large volume parenteral (LVP) products, and any other drug products required to be sterile or labeled as sterile. Center for Biologics Evaluation and Research (CBER) regulated products and veterinary drug products are excluded from coverage under this program.
The guidance information is tailored to sterile manufacturing operations and should be used in conjunction with the Compliance Program for Drug Manufacturing Inspections (CP 7356.002).
Process Validation is Key important factor for the Pharmaceutical Industry to maintain Consistent Quality in product which claimed by the manufacturer.
In the last year or so the FDA and the EMA have issued new guidance/ draft guidance on "Process Validation".These align process validation activities with a product lifecycle concept and the International Conference on Harmonisation (ICH) guidances for industry, Q8(R2) Pharmaceutical Development, Q9 Quality Risk Management, and Q10 Pharmaceutical Quality System. The earlier guidelines were developed before the elaboration of the new ICH guidelines.With these new guidelines, additional opportunities are available to verify the control of the process by alternative means to the manufacture of traditional process validation batches. The main objective of process validation remains that a process design yields a product meeting its pre-defined quality criteria. ICH Q8, Q9 and Q10 provide a structured way to define product critical quality attributes, design space, the manufacturing process and the control strategy. ICH Q8 refers to an ‘enhanced’ approach to pharmaceutical development which includes an alternative to the traditional process validation.
Continuous process verification [see definition in ICH Q8(R2) glossary] can be utilised in process validation protocols for the initial commercial production and for manufacturing process changes for the continual improvement throughout the remainder of the product lifecycle.
There is now a new paradigm in process validation. This presentation has been prepared from material available from FDA , EMA and ICH for beginners to have an overview of the new paradigm.
Cleaning validation is one of the major and critical activity in pharmaceutical operations
The four basic requirement of cGmp are …
Identity
Safety*
Strength
Purity*
This presentation covers the manufacture and testing of all sterile drug products, including drugs that are sterilized by filtration or other means and aseptically processed, and drug products that are terminally sterilized. The type of products covered include sterile bulk drugs, ophthalmic drugs, otic dosage forms, small volume parenteral (SVS) products for small molecule and licensed biological
therapeutic drug products, large volume parenteral (LVP) products, and any other drug products required to be sterile or labeled as sterile. Center for Biologics Evaluation and Research (CBER) regulated products and veterinary drug products are excluded from coverage under this program.
The guidance information is tailored to sterile manufacturing operations and should be used in conjunction with the Compliance Program for Drug Manufacturing Inspections (CP 7356.002).
Process Validation is Key important factor for the Pharmaceutical Industry to maintain Consistent Quality in product which claimed by the manufacturer.
This presentation is for those who want to go in the field of BIOTECHNOLOGY.
All career related things are mentioned in this ppt.
Hope it helps you !!!
Process validation is a requirement of the current Good Manufacturing Practices (cGMP) Regulations for Finished Pharmaceuticals. Validation is defined as a documented program that provides a high degree of assurance that a specific process, method, or system will consistently produce a result meeting pre-determined acceptance criteria.
This presentation is all about biotechnology. It is about the basic aspects of Biotechnology and covers a lot of topics under biotechnology, recombinant DNA technology. This is specifically for the HSC students of Mumbai. I hope that it helps.
Integrity Bio is a protein formulation development, fill finish, and drug delivery CMO. Injectable formulations include protein,antibody, vaccine, and peptide. http://www.integritybio.com
Stabicon specialized in managing product quality process, upgrading and introducing advanced technology into products. We are proud to lay a foundation for prosperous future in prevention and cure segment, future medicine & FMCG business. Established in September 2010. Team experience across from design to concept, lab to commercialization of product and with competent technical experts. Automated process driven and prepared for integration with partner site for transparency and real time access on each application.
Participate in the full, interactive on-demand webinar here: https://bit.ly/ProcessValWebinar
Process validation is a complex step in the transition to commercial scale manufacturing. While Quality By Design (QBD) is the standard option for a risk-mitigating process validation strategy, there are other options for more flexibility and speed. Join our webinar to learn how outsourcing to a CDMO, able to take an adaptive, risk-based validation approach, will accelerate your time to market.
In this webinar, you will discover more about:
• How outsourcing to a CDMO partner in late-stage will increase flexibility and speed
• How a risk-based approach can help you optimize your process validation strategy
• How we have implemented a risk-based approach for our clients via case studies
009 what are the systems validation protocol methods at atl 05 28-2015atlmarketing
If your product must meet the requirements of FDA cGMP, 21 CFR 210, 211, 820, ISO-9000, ISO-13485, or MDD/93/42/EEC (for the CE Mark), there are three very critical elements you must have to be in regulatory compliance. First, you must have a sound and strong Quality Management System (QMS). This is an expression of WHAT you do (your quality policies and structure). Second, you must have reliable Standard Operating Procedures (SOP’s). These are expressions of HOW YOU DO THINGS.
Missing in the above two items is an expression of HOW WELL YOU DO WHAT YOU DO? This is where you must establish your “Systems Validation Protocol” (SVP). Your SVP is an expression of how well your system is working (for example, this can be expressed in overall product conformance percentage or in defects per million for your various products). The SVP is a living and continuous document based on your quality records. The ATL White Paper “What Are The Systems Validation Protocol Methods At ATL?” is our attempt to share with you a sound approach to Systems Validation and the various protocols that you can use.
PAT and QbD concepts in designing the LiMS and other Electronic systems in La...balakrishna t
tQmlab® is the premier management system for GxP operations and for supporting regulatory submissions. It delivers transformational productivity for QA/QC labs supporting customised workflows for quality control of drugs, stability testing, product release testing and post-release quality testing.
#Stabicon product certification process management strives to improve processes and align the needs of regulatory with client objectives on quality product distribution channel. This gives transparency to the process making it more efficient. It include review and testing process to validate that certified products meet certain standards and comply with a stated designed specification/requirement. Product certification process works towards improving efficiency across the various project stakeholders by helping product evaluation and implement best practices.
Study 5: Pre-commissioning Safety Review
CONTENTS
5.0 PURPOSE
5.0.1 Team
5.0.2 Timing
5.0.3 Preparation
5.0.4 Documentation
HAZARD STUDY 5: APPLICATION
5.1 TOUR OF THE PROJECT
5.2 REVIEW OF HAZARD STUDY 5
Description:
This course will provide participants with a thorough understanding of the requirements of process validation for both small molecule (pharmaceuticals) and Biologic products. They will learn how to establish an effective process validation system and integrate it with other systems such as Risk Management, Corrective and Preventive Action and Supplier Management.
Participants will learn how to develop rigorous protocols and reports, as well as create monitoring programs to ensure that defined critical parameters remain in control. The course will also review validation requirements for systems that generate electronic signatures and records as most new processes have this capability.
Similar to Process Validation Presentation from BioTechLogic (20)
Process Validation & Regulatory Strategies for Fast-track and Breakthrough Th...Peter Dellva
BioTechLogic's Tracy TreDenick delivered a compelling presentation discussing process validation & regulatory strategies for Fast-Track and Breakthrough Therapies at BPI West - March 20, 2018
Quick Overview: Pharmaceutical Data IntegrityPeter Dellva
Brief overview of the most important aspects of pharmaceutical data integrity. Slideshare includes pharmaceutical and biopharmaceutical industry key resources.
5 Critical Areas of Combination Drug CompliancePeter Dellva
This slideshare walks through five critical areas of combination drug compliance including: What is 21 CFR Part 4, FDA’s Office of Combination Products, Compliance for legacy combination products, Stability study strategy and more
Bringing Legacy Combination Products into Compliance with 21 CFR Part 4Peter Dellva
Presentation provides an overview of 21 CFR Part 4 and discusses the approach to assure legacy combination drug products are compliant with the final rule.
Approaches to regulatory approval and process validation often must be quite different than traditional approaches. This presentation walks through nine approaches that might be helpful to your project.
Regulatory approval and validations approaches often have to be a bit different when working to get an expedited approval drug to market. This presentation discusses 9 approaches to smooth the process
Remote sensing and monitoring are changing the mining industry for the better. These are providing innovative solutions to long-standing challenges. Those related to exploration, extraction, and overall environmental management by mining technology companies Odisha. These technologies make use of satellite imaging, aerial photography and sensors to collect data that might be inaccessible or from hazardous locations. With the use of this technology, mining operations are becoming increasingly efficient. Let us gain more insight into the key aspects associated with remote sensing and monitoring when it comes to mining.
Skye Residences | Extended Stay Residences Near Toronto Airportmarketingjdass
Experience unparalleled EXTENDED STAY and comfort at Skye Residences located just minutes from Toronto Airport. Discover sophisticated accommodations tailored for discerning travelers.
Website Link :
https://skyeresidences.com/
https://skyeresidences.com/about-us/
https://skyeresidences.com/gallery/
https://skyeresidences.com/rooms/
https://skyeresidences.com/near-by-attractions/
https://skyeresidences.com/commute/
https://skyeresidences.com/contact/
https://skyeresidences.com/queen-suite-with-sofa-bed/
https://skyeresidences.com/queen-suite-with-sofa-bed-and-balcony/
https://skyeresidences.com/queen-suite-with-sofa-bed-accessible/
https://skyeresidences.com/2-bedroom-deluxe-queen-suite-with-sofa-bed/
https://skyeresidences.com/2-bedroom-deluxe-king-queen-suite-with-sofa-bed/
https://skyeresidences.com/2-bedroom-deluxe-queen-suite-with-sofa-bed-accessible/
#Skye Residences Etobicoke, #Skye Residences Near Toronto Airport, #Skye Residences Toronto, #Skye Hotel Toronto, #Skye Hotel Near Toronto Airport, #Hotel Near Toronto Airport, #Near Toronto Airport Accommodation, #Suites Near Toronto Airport, #Etobicoke Suites Near Airport, #Hotel Near Toronto Pearson International Airport, #Toronto Airport Suite Rentals, #Pearson Airport Hotel Suites
Premium MEAN Stack Development Solutions for Modern BusinessesSynapseIndia
Stay ahead of the curve with our premium MEAN Stack Development Solutions. Our expert developers utilize MongoDB, Express.js, AngularJS, and Node.js to create modern and responsive web applications. Trust us for cutting-edge solutions that drive your business growth and success.
Know more: https://www.synapseindia.com/technology/mean-stack-development-company.html
Enterprise Excellence is Inclusive Excellence.pdfKaiNexus
Enterprise excellence and inclusive excellence are closely linked, and real-world challenges have shown that both are essential to the success of any organization. To achieve enterprise excellence, organizations must focus on improving their operations and processes while creating an inclusive environment that engages everyone. In this interactive session, the facilitator will highlight commonly established business practices and how they limit our ability to engage everyone every day. More importantly, though, participants will likely gain increased awareness of what we can do differently to maximize enterprise excellence through deliberate inclusion.
What is Enterprise Excellence?
Enterprise Excellence is a holistic approach that's aimed at achieving world-class performance across all aspects of the organization.
What might I learn?
A way to engage all in creating Inclusive Excellence. Lessons from the US military and their parallels to the story of Harry Potter. How belt systems and CI teams can destroy inclusive practices. How leadership language invites people to the party. There are three things leaders can do to engage everyone every day: maximizing psychological safety to create environments where folks learn, contribute, and challenge the status quo.
Who might benefit? Anyone and everyone leading folks from the shop floor to top floor.
Dr. William Harvey is a seasoned Operations Leader with extensive experience in chemical processing, manufacturing, and operations management. At Michelman, he currently oversees multiple sites, leading teams in strategic planning and coaching/practicing continuous improvement. William is set to start his eighth year of teaching at the University of Cincinnati where he teaches marketing, finance, and management. William holds various certifications in change management, quality, leadership, operational excellence, team building, and DiSC, among others.
The world of search engine optimization (SEO) is buzzing with discussions after Google confirmed that around 2,500 leaked internal documents related to its Search feature are indeed authentic. The revelation has sparked significant concerns within the SEO community. The leaked documents were initially reported by SEO experts Rand Fishkin and Mike King, igniting widespread analysis and discourse. For More Info:- https://news.arihantwebtech.com/search-disrupted-googles-leaked-documents-rock-the-seo-world/
What is the TDS Return Filing Due Date for FY 2024-25.pdfseoforlegalpillers
It is crucial for the taxpayers to understand about the TDS Return Filing Due Date, so that they can fulfill your TDS obligations efficiently. Taxpayers can avoid penalties by sticking to the deadlines and by accurate filing of TDS. Timely filing of TDS will make sure about the availability of tax credits. You can also seek the professional guidance of experts like Legal Pillers for timely filing of the TDS Return.
[Note: This is a partial preview. To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations]
Sustainability has become an increasingly critical topic as the world recognizes the need to protect our planet and its resources for future generations. Sustainability means meeting our current needs without compromising the ability of future generations to meet theirs. It involves long-term planning and consideration of the consequences of our actions. The goal is to create strategies that ensure the long-term viability of People, Planet, and Profit.
Leading companies such as Nike, Toyota, and Siemens are prioritizing sustainable innovation in their business models, setting an example for others to follow. In this Sustainability training presentation, you will learn key concepts, principles, and practices of sustainability applicable across industries. This training aims to create awareness and educate employees, senior executives, consultants, and other key stakeholders, including investors, policymakers, and supply chain partners, on the importance and implementation of sustainability.
LEARNING OBJECTIVES
1. Develop a comprehensive understanding of the fundamental principles and concepts that form the foundation of sustainability within corporate environments.
2. Explore the sustainability implementation model, focusing on effective measures and reporting strategies to track and communicate sustainability efforts.
3. Identify and define best practices and critical success factors essential for achieving sustainability goals within organizations.
CONTENTS
1. Introduction and Key Concepts of Sustainability
2. Principles and Practices of Sustainability
3. Measures and Reporting in Sustainability
4. Sustainability Implementation & Best Practices
To download the complete presentation, visit: https://www.oeconsulting.com.sg/training-presentations
Improving profitability for small businessBen Wann
In this comprehensive presentation, we will explore strategies and practical tips for enhancing profitability in small businesses. Tailored to meet the unique challenges faced by small enterprises, this session covers various aspects that directly impact the bottom line. Attendees will learn how to optimize operational efficiency, manage expenses, and increase revenue through innovative marketing and customer engagement techniques.
Personal Brand Statement:
As an Army veteran dedicated to lifelong learning, I bring a disciplined, strategic mindset to my pursuits. I am constantly expanding my knowledge to innovate and lead effectively. My journey is driven by a commitment to excellence, and to make a meaningful impact in the world.
Putting the SPARK into Virtual Training.pptxCynthia Clay
This 60-minute webinar, sponsored by Adobe, was delivered for the Training Mag Network. It explored the five elements of SPARK: Storytelling, Purpose, Action, Relationships, and Kudos. Knowing how to tell a well-structured story is key to building long-term memory. Stating a clear purpose that doesn't take away from the discovery learning process is critical. Ensuring that people move from theory to practical application is imperative. Creating strong social learning is the key to commitment and engagement. Validating and affirming participants' comments is the way to create a positive learning environment.
India Orthopedic Devices Market: Unlocking Growth Secrets, Trends and Develop...Kumar Satyam
According to TechSci Research report, “India Orthopedic Devices Market -Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030”, the India Orthopedic Devices Market stood at USD 1,280.54 Million in 2024 and is anticipated to grow with a CAGR of 7.84% in the forecast period, 2026-2030F. The India Orthopedic Devices Market is being driven by several factors. The most prominent ones include an increase in the elderly population, who are more prone to orthopedic conditions such as osteoporosis and arthritis. Moreover, the rise in sports injuries and road accidents are also contributing to the demand for orthopedic devices. Advances in technology and the introduction of innovative implants and prosthetics have further propelled the market growth. Additionally, government initiatives aimed at improving healthcare infrastructure and the increasing prevalence of lifestyle diseases have led to an upward trend in orthopedic surgeries, thereby fueling the market demand for these devices.
Cracking the Workplace Discipline Code Main.pptxWorkforce Group
Cultivating and maintaining discipline within teams is a critical differentiator for successful organisations.
Forward-thinking leaders and business managers understand the impact that discipline has on organisational success. A disciplined workforce operates with clarity, focus, and a shared understanding of expectations, ultimately driving better results, optimising productivity, and facilitating seamless collaboration.
Although discipline is not a one-size-fits-all approach, it can help create a work environment that encourages personal growth and accountability rather than solely relying on punitive measures.
In this deck, you will learn the significance of workplace discipline for organisational success. You’ll also learn
• Four (4) workplace discipline methods you should consider
• The best and most practical approach to implementing workplace discipline.
• Three (3) key tips to maintain a disciplined workplace.
RMD24 | Debunking the non-endemic revenue myth Marvin Vacquier Droop | First ...BBPMedia1
Marvin neemt je in deze presentatie mee in de voordelen van non-endemic advertising op retail media netwerken. Hij brengt ook de uitdagingen in beeld die de markt op dit moment heeft op het gebied van retail media voor niet-leveranciers.
Retail media wordt gezien als het nieuwe advertising-medium en ook mediabureaus richten massaal retail media-afdelingen op. Merken die niet in de betreffende winkel liggen staan ook nog niet in de rij om op de retail media netwerken te adverteren. Marvin belicht de uitdagingen die er zijn om echt aansluiting te vinden op die markt van non-endemic advertising.
RMD24 | Debunking the non-endemic revenue myth Marvin Vacquier Droop | First ...
Process Validation Presentation from BioTechLogic
1. TECH
LOGIC
BioTechLogic, Inc.
BIO TECH
LOGICBIO ®
Stage 1:
Process Design
Stage 2: Process
Qualification
Stage 3: Continued
Process Verification
Explore Process
Validation
Click on a link below (Stage 1, 2, or 3) to
view a presentation on the various stages
of Process Validation and how
BioTechLogic can help you succeed in your
validation efforts.
Slide 1
Company Confidential
2. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Slide 2
Company Confidential
BioTechLogic was founded by former Searle/Pharmacia/Pfizer
colleagues.
BioTechLogic, Inc. provides biopharmaceutical manufacturing and
regulatory consulting services with strategic and hands-on experience
to assist clients in bringing their products to market by augmenting
and optimizing an organization’s resources.
Our Expertise is Process Validation, CMC Regulatory Services and
Quality Systems.
About BioTechLogic, Inc.
3. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Slide 3
Company Confidential
Did you Know Since 2004 …
Our Company experience includes over 300 different projects with 50+ different
clients.
We have supported 22 different biologically derived compounds, including 11
recombinant proteins, 4 vaccines, 3 antibodies, 2 blood based-products, 1 fusion
protein and 1 pancreatic enzyme.
We have collaborated on 7 synthesized macromolecules, including 5 Oligonucleotide
and 2 peptide projects.
BioTechLogic has led 9 Process Validation Programs, 6 of which have been
submitted and accepted by the FDA and/or EMA to date.
Involvement with 2 FDA approved Biological products (BLA’s), 2 FDA approved
Drug Products (NDA’s), 2 FDA approved Drug/Device Combination Products
(PMA’s), and another Biologic which just received a positive opinion from EMA (MAA).
We have served as the primary CMC author for 5 IND’s, 5 BLA’s, 5 MAA’s and
1 IMPD.
2 small molecule compounds, including a solid oral dosage and a parenteral.
About BioTechLogic, Inc.
4. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
BioTechLogic’s Expert Services
• Manufacturing: On-Site Third Party Contract Manufacturing Support,
Statistical Process Controls, Supply Assurance
• Project Management: Project Plans and Schedules, Project Management,
Team Organization, Meeting Management, Action Item Tracking, Budget
Tracking
• Process Validation: Strategy, Critical Process Parameter Evaluation,
Validation Protocols and Reports, Support Validations (Resin Re-Use,
Membrane Re-Use, Hold times, Loading Studies, etc.)
• Quality Assurance: Audits, Global Inspection Readiness, Quality Systems,
On-Site Senior Management
• Supply Chain: Site Selection, Make vs Buy, Due Diligence
Slide 4
Company Confidential
5. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
BioTechLogic’s Expert Services
• Combination Products: Regulatory Strategy, Dossiers, CE Marking
process
• Regulatory Submissions: Briefing Packages, Agency Responses,
IND’s/IMPD’s, BLA/MAA, PAS or ROW Filings, 510K, PMA’s
• Process Development: Development Reports, Design of Experiments
(DOE), Technology Implementation, Transfer and Scale-up, Comparability,
Troubleshooting, Technology and Facility Evaluations
• BioAnalytical Services: Strategy, Hands-On, Expert Review, Analytical
Method Transfer
Slide 5
Company Confidential
6. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Slide 6
Company Confidential
The BioTechLogic Advantage
Our success is due to our ability to serve as the technical expert and consultant,
yet be the hands-on resource that drives and executes the plan.
Most Ex-FDA and Consultants
Our service advantage is that we have depth and breadth of knowledge. Our staff
began their careers in R&D or on the Manufacturing floor, and has a depth of
understanding that goes beyond typical consultants. We have worked on many
different types of technologies to benchmark best practices, and have taken numerous
biopharmaceutical drugs through commercialization.
7. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Biologic Process Validation Experience
– 2002: Somavert® (Growth Hormone Antagonist) - PEGylated Protein [FDA and EMA Approval 2003]
• API and Drug Product PV Strategy and PV Support Documentation Generation
– 2003: Macugen® (pegaptanib sodium injection) - PEGylated Oligonucleotide [FDA Approval 2004 and
EMA Approval 2005]
• API PV Strategy, CMO Site PV Readiness and PV Support Documentation Generation
– 2004-2005: FAb - PEGylated Antibody Fragment [FDA Approval 2008 and EMA 2009]
• API and Drug Product PV Strategy, CMO Site PV Readiness and PV Support Documentation
Generation
– 2006-2008: PolyHeme® - a Novel Therapeutic Hemoglobin (Oxygen Carrier) [FDA 2009 No CMC Issues]
• API Process Validation Gap Assessment
• API PV Readiness Support, Development and Comparability Reports
• 2009; Product not approved by FDA citing clinical deficiencies. No CMC issues.
– 2007-2008: Asparaginase - Recombinant Protein [EMA 2011 submission]
• On-Site Analytical Support, Support Validations, and PV Project Management
– 2008: Vaccine - National Defense Program
• Process Validation Responses to NIH, BARDA and FDA
• Process Validation Strategy for API and Drug Product, and PV Support Documentation Generation
Slide 7
Company Confidential
8. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Biologic Process Validation Experience
– 2009: Vaccine
• PV Strategy, Site PV Readiness as well as Support Validation Documentation and PV Protocols for
Adjuvant, API and Drug Product
• Qualification Batches completed in 2009
– 2011: Generic Fusion Recombinant Protein (on-going)
• PV Strategy, Support Validation Documentation and Drug Substance PV Protocols
• Qualification Batches to be completed in 2011
– 2011: Generic Small Molecule Injectable (pending)
• PV Strategy, Site PV Readiness as well as Support Validation Documentation and Drug Product PV
Protocols
• Qualification Batches to begin in 2011
– 2011: Generic Recombinant Protein (pending)
• PV Strategy, Site PV Readiness as well as Support Validation Documentation and PV Protocols Drug
Substance and Drug Product
• Qualification Batches to begin in 2011
Slide 8
Company Confidential
10. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Slide 10
Company Confidential
The scope of this case study is to provide and evaluate
data obtained from small-scale Ion Exchange
Chromatography runs performed within defined parameter
limits in experiments planned and executed according to
Design of Experiments (DOE).
Process Background
12. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Risk Assessment
Slide 12
Company Confidential
Operating Parameter Normal Operating Range Potential Effect(s) of Failure SEV OCC DET RPN
UV at Start of AEX Fraction Collection > 0.50 AU Product loss, quality 9 4 2 72
UV at End of AEX Fraction Collection < 20% of maximum peak height Product loss, quality 9 4 2 72
Elution Gradient
8% per CV
(20 – 100% B over 10 CV)
Inconsistent quality 8 2 4 64
Equilibration volume ≥ 5 CV Product loss, quality 9 2 1 18
Load flow rate 100 – 120 L/h (Target: 110 L/h) Inconsistent quality 4 1 3 12
Wash flow rate 100 – 120 L/h (Target: 110 L/h) Inconsistent quality 4 1 3 12
Elution flow rate 100 – 120 L/h (Target: 110 L/h) Inconsistent quality 4 1 3 12
Pre-Equilibration flow rate 100 – 120 L/h (Target: 110 L/h) Longer equilibration 4 1 3 12
Fraction Volume
F1 – F3: 0.2 CV
F4+: 0.1 CV
Product loss, quality 9 1 1 9
Wash volume ≥2 CV Inconsistent quality 5 1 1 5
Fraction Mixing Speed 65 rpm Inconsistent quality 4 1 1 4
Fraction Mixing Time 20 - 30 min Inconsistent quality 4 1 1 4
Pool Mixing Time
10 – 15 min
Non-homogeneity, inconsistent
sampling/yield
4 1 1 4
Pool Mixing Speed
100 rpm
Non-homogeneity, inconsistent
sampling/yield
4 1 1 4
Pre-Equilibration volume ≥ 4 CV Longer equilibration 3 1 1 3
WFI Rinse volume ≥ 3 CV Longer equilibration 3 1 1 3
WFI Rinse flow rate 100 – 120 L/h (Target: 110 L/h) Longer equilibration 1 1 1 3
Equilibration flow rate 100 – 120 L/h (Target: 110 L/h) Product loss, quality 3 1 1 3
In-Process Control Limits
Column Load 15 – 25 g / L resin
Column Bed Height 30 ± 3 cm
Column Backpressure during
Equilibration, Load, Wash, and Elution
< 3 bar
Effluent pH at end of Equilibration
± 0.3 pH Units of Equilibration
Buffer pH
Effluent Cond. at end of Equilibration
± 1 mS/cm Units of Equilibration
Buffer Conductivity
Effluent UV at the end of Equilibration Zero
Fraction Pooling Criteria (RP-HPLC) ≥ 95% Main Peak
13. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Risk Assessment
The parameters selected for evaluation in this study were
the UV at start of fraction collection, UV at end of fraction
collection, gradient slope, and resin load.
Dependent variables analyzed were protein recovery yield
and purity by RP-HPLC.
Slide 13
Company Confidential
Input parameter
Testing limits
Output parameters
Lower Upper
UV at the beginning of
fraction collection (AU)
0.40 0.60
Purity by RP-HPLC (≥ 95%)
Step yield (≥ 75%)
UV at the end of pooling
(% from peak max)
10 30
Gradient slope (% per CV) 4.0 12.0
Resin Load, (g/L resin) 15 25
14. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
DOE
Slide 14
Company Confidential
Pattern Exp. No.:
UV at the start
of fraction
collection
(AU)
UV at the end
of pooling
(% peak max)
Gradient
slope
(% per CV)
Resin Load
(g/L)
−−−− 1 0.4 10 4 15
0000 2 0.5 20 8 20
0000 3 0.5 20 8 20
−++− 4 0.4 30 12 15
0000 5 0.5 20 8 20
++−− 6 0.6 30 4 15
+−−+ 7 0.6 10 4 25
++++ 8 0.6 30 12 25
+−+− 9 0.6 10 12 15
−−++ 10 0.4 10 12 25
0000 11 0.5 20 8 20
−+−+ 12 0.4 30 4 25
Note: It is important to randomize the run order to assure the
independence of your observations and reduce the chances of a
mistake by the operator.
15. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Experimental Results
• A summary of the variable parameters for each of the
Ion Exchange Chromatography runs as well as the
Outputs, step yield and eluate purity by RP-HPLC are
listed in the following table.
• Runs that did not meet the defined acceptance criteria
are shaded to indicate run failure
Slide 15
Company Confidential
17. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Statistical data analysis
• For evaluation of statistically significant effects of factors
on protein quality and quantity, the JMP statistical
software package was used applying the Standard Least
Squares model for Effect Leverage.
• The model was run separately for two output parameters
of yield and purity by RP-HPLC.
• The fractional factorial model was initially run with the
inclusion of all single factor and some two-factor
interactions as model effects (Resolution IV). Due to
resource and time constraints, a higher resolution study
was not possible.
Slide 17
Company Confidential
18. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Statistical Model Parameter Estimates for
Step Yield
• The final model used for assessment all four primary
effects and two factor interactions listed above.
• There were two significant main effects and one
significant interaction. These conclusions were
graphically represented in the main effects leverage
plots and interaction contour plots.
Slide 18
Company Confidential
19. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Main Effect Leverage Plots for Step Yield
Slide 19
Company Confidential
a. UV at Start Collection b. UV at End Collection
c. Gradient Slope d. Resin Load
20. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Statistical Model Parameter Estimates
for Purity by RP-HPLC
• The final model used for assessment included all four
primary effects (excluding resin load) as well as three
two-factor interactions.
Slide 20
Company Confidential
21. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Two-Factor Interaction Contour Plots
for Purity by RP-HPLC
Slide 21
Company Confidential
a. UV at End Collection x Gradient Slope b. UV at Start Collection x Gradient Slope
0
UV @ End (%)
Gradient Slope (%/CV)
Step Yield (%)
0
UV @ Start (AU)
Resin Load (g/L resin)
Step Yield (%)
22. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Confirmation of Results
• There is one area of the tested design space that represents process
failure space with regard to step yield, run 8. In order to ensure that
the step yield acceptance criterion is always met when the process is
operated within its defined PARs, the design space was modified
and two additional runs were performed to augment the initial
design.
• We chose to tighten the gradient slope upper limit to 11% as it was
determined to be easy to control and the most significant primary
effect for step yield in our initial analysis.
• None of the experimental runs for the tightened limits failed the
acceptance criterion for step yield. This confirms the predicted
design space from the initial study.
Slide 22
Company Confidential
23. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Design Space vs. Defined Control Space
Based on the models
generated for each of the
defined process outputs, a
three-dimensional plot was
generated to graphically
show the process control
space with regard to the
experimentally defined
design space
Slide 23
Company Confidential
24. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Conclusions
• The results of this DOE study confirm the predicted
design space from the initial study.
• Based on our findings we determined that the IPC limits
we chose for the three input parameters were
appropriate with the exception of Gradient Slope.
• As a result we tightened our control limits.
• The IPC limits for resin load were also determined to be
set appropriately.
Slide 24
Company Confidential
25. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Final Parameter Limits
Slide 25
Company Confidential
Operating Parameter
Normal Operating Range
(NOR)
Experimentally Confirmed
Ranges
UV at the beginning of
pooling, % from peak max Target: > 0.5 AU 0.4 – 0.6 AU
UV at the end of pooling, %
from peak max Target: 20% 10 – 30%
Gradient slope, % per CV Target: 8% 4 – 11%*
Performance Parameter In-Process Acceptance Criterion
Resin Load, g/L 15 – 25 g/L
* Note: The claimed experimentally confirmed range is slightly tighter than the design space in that it takes the worst-case data point to
support the higher end of the range.
27. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Slide 27
Company Confidential
Lifecycle Approach to Process Validation
“The lifecycle concept links product and process development,
qualification of the commercial manufacturing process, and
maintenance of the process in a state of control during routine
commercial production.”
- FDA Guidance for Industry, Process Validation: General Principles and Practices
(January, 2011)
“Process validation involves the collection and evaluation of
data, from the process design stage throughout production,
that establish scientific evidence that a process is capable of
consistently delivering a quality drug substance.”
- ICH Q11, Development and Manufacture of Drug Substances
(May, 2011)
28. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Slide 28
Company Confidential
Three Stages of Process Validation
A high degree of assurance in the
performance of the manufacturing
process must be attained prior to
commercial distribution (i.e., “initial”
validation)
Ongoing assurance of the “validated
state”…as materials, equipment,
production environment, personnel,
and manufacturing procedures
change.
29. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
• The “burden of proof” is not merely three successful,
consecutive conformance batches, but rather a
manufacturer’s high degree of assurance.
• How does one gain a high degree of assurance in a
manufacturing process?
Understand sources of variation
Detect the presence and degree of variation
Understand the impact of variation on the process and on product
attributes
Control the variation in a manner commensurate with the risk it
represents to the process and product
- FDA Guidance for Industry, Process Validation: General Principles and Practices
(January, 2011)
Slide 29
Company Confidential
Burden of Proof
30. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
The BioTechLogic Approach to PV
Slide 30
Company Confidential
• Understand Function of Each Unit Operation
• Define Process Inputs and Outputs
• Determine Potential Critical Operating Parameters, Steps or Raw
Materials by Risk Assessment
• Experimentally define NOR and PAR for critical parameters using
DOE and Statistical Assessment
• Based on DOE studies, establish final list of Critical/Key Operating
Parameters
• Parameter Evaluation / Pre-Qualification Report
• Execute Support Validation Studies to Define Ranges for Process
Definition (Holds, Re-use, etc)
• Final Process Control Strategy
• Define the Process by Finalizing the Batch Record
• Utilities, Facility, Equipment, Components, Raw Materials and
Analytical Readiness
• Write Process Performance Qualification Protocol(s)
• Execute Process Performance Qualification Batches
• Write Process Performance Qualification Report(s)
• Create Continued Process Verification strategy
• Compile and assess CPV data after each batch
• Maintain/Assess Qualified Process via appropriate CAPA and Change
Control
Process Design
Process
Qualification
Continued Process
Verification
ProcessValidation
33. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Slide 33
Company Confidential
Map of Typical DP Process Validation
Process Data
Trending
Process
Characterization
Studies
Infusion bag
Extractable/
Leachable
Filter Validation
Fill Accuracy
Mixing Study
Post Filtration
Processing Time
Pre-Filtration Hold
Time
Shipping Validation
Utility
Qualification
Equipment
Qualification
Equipment
Cleaning
Validation
Raw Material
Analysis
Vendor
Qualification
Component
Compatibility
In-Process
Method
Validation
Release
Methods
Validation
Analytical Method
Qualification/
Validation
Raw Materials &
Component
Qualification
Facility
Qualification
Process Control
Strategy
Commercial
Manufacturing
Instructions
Process
Qualification
Continued
Process
Verification
34. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
How Can BTL Help You Succeed (Stage 1)?
• Define Process Inputs and Outputs
– Review production batch records to compile comprehensive list of process parameters
– Write Parameter Justification Report to define how parameters and ranges were established
– Write Process Development Reports to appropriately capture process knowledge
• Determine Potential Critical Operating Parameters, Steps or Raw Materials by Risk Assessment
– Lead comprehensive, multi-disciplinary process risk assessment to rank potential sources of process
variation
– Write Risk Assessment Reports throughout clinical development (lifecycle approach means risk
assessment are being re-visited as process knowledge increases)
• Experimentally define NOR and PAR for critical parameters using DOE and Statistical Assessment
– Design an experimental approach that will ensure a risk-based and science-based approach to determining
parameter criticality
– Establish and qualify appropriate scaled-down models
– Ensure that DOE studies are appropriately designed and interpreted, with experience in JMP, Design-
Expert, and MiniTab statistical software
– Execute Quality by Design
• Based on DOE studies, establish final list of Critical/Key Operating Parameters
– Facilitate decision-making with regard to formal PPQ acceptance criteria
– Implement PDA Technical Report 42 approach for parameter designation to ensure consistency with
industry standards
Slide 34
Company Confidential
35. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
How Can BTL Help You Succeed (Stage 1)?
Slide 35
Company Confidential
• Parameter Evaluation / Pre-Qualification Report
– Write a comprehensive Parameter Evaluation Report as the “roadmap” to all the various risk assessments
and process characterization reports
– Add benefit in that, if formatted appropriately, this document forms the basis for BLA/MAA Section 3.2.S.2.4
• Execute Support Validation Studies to Define Ranges for Process Definition
– Design, review, and/or write protocols and reports for process validation support studies, including resin
lifetime studies, membrane lifetime studies, media hold studies, in-process hold studies, buffer hold studies,
process-related impurities removal studies, filter validation, container/closure validation, etc.
• Final Process Control Strategy
– Write a Process Control Strategy, which is a summary of results from the validation support studies and the
process characterization work, and provides the critical link between Stages 1 and 2 of Process Validation
• Define the Process by Finalizing the Batch Record
– Ensure that the highest quality batch records are carried forward into Process Performance Qualification
(Stage 2) based on extensive scientific/process and quality/regulatory experience
36. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Slide 36
Company Confidential
How Can BTL Help You Succeed (Stage 2)?
• Utilities, Facility, Equipment, Components, Raw Materials and Analytical Readiness
– Ensure that appropriate risk assessments and qualifications are in place for production facilities, utilities,
and equipment
– Ensure that appropriate raw materials and components risk assessments and vendor qualifications have
been performed
– Ensure that appropriate analytical method qualification has occurred prior to Stage 2 Validation
• Write Process Performance Qualification Protocol(s)
– Ensure that appropriate assessment of historical data (both small-scale and production-scale) has been
completed to define the appropriate number of PPQ batches to define in PPQ protocol(s)
– Ensure that PPQ approach is appropriately connected back to process knowledge gleaned during Stage 1
Validation
• Execute Process Performance Qualification Batches
– Provide Man-in-Plant support prior to and/or during PPQ campaign to facilitate communication between
client and manufacturing facility and to ensure immediate oversight of production and to provide
troubleshooting capabilities
• Write Process Performance Qualification Report(s)
37. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Slide 37
Company Confidential
How Can BTL Help You Succeed (Stage 3)?
• Create Continued Process Verification strategy
– Guide a multi-disciplinary team through a risk-based and science-based approach to a step-down plan from
PPQ sampling and testing strategy
– Write a CPV Master Plan/Strategy Document
– Guide manufacturers in implementation of sponsor’s CPV plan
– Review manufacturers quality systems to ensure appropriate mechanisms are in place to feed appropriate
data/information from systems into overall CPV assessment
• Compile and assess CPV data after each batch
– Ensure appropriate systems are in place at manufacturer to compile CPV data/information and to
communicate the “validated state” across the organization in a timely manner
• Maintain/Assess Qualified Process via appropriate CAPA and Change Control
– Review change control documentation to ensure compliance with regulatory expectations
40. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Introduction
Slide 40
Company Confidential
• Post-validation reporting requirements essentially have
not changed. The PV Guidance document repeatedly
cites CFR 211.180(e), which is a 30 year-old regulation.
• What’s “new” is inherent in the name of Stage 3 –
Continued Process Verification and emphasized in the
first line of Section IV.D in the guidance document:
“The goal of the third validation stage is continual assurance that the
process remains in a state of control (the validated state) during
commercial manufacture.” (FDA’s Guidance for Industry – Process
Validation: General Principles and Practices, 2011)
41. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Two Categories of CPV Information
Slide 41
Company Confidential
Category #1 = Process/Product Data Category #2 = Events-Based Data
• Process trends
• RM/Component
Quality
• In-Process
Material Quality
• Finished Product
Quality
• Defect complaints
• OOS findings
• Process deviation
reports
• Operator
observations
• Batch record reviews
• Adverse events
reports
42. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Goals of a Comprehensive CPV Program
1. To combine the evaluation of process data and events-based data
so that process and product are constantly “informing each other”.
2. To review both types of data in a “continual” manner so that it’s not
too late to take action to minimize patient risk and save batches.
3. To document such data according to good process knowledge
management principles so that valuable information is not lost.
4. To effectively communicate such information across the
organization so that quick decisions can be made to ensure patient
safety.
Slide 42
Company Confidential
43. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
How Do We Implement CPV Objectives?
• Leverage information gleaned during Stage 1
and Stage 2 validation to minimize the “burden
of proof” for Stage 3.
• More information is not always better. Be
selective (based on risk-based and science-
based “filters”).
• Utilize existing quality systems. But, again, be
selective about what gets fed into the CPV
program.
Slide 43
Company Confidential
45. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Key Point
Post-Approval Process Validation Reporting
is more about getting key personnel within an
organization informed and on the same page
regarding the state of process control than it
is about communicating that information to
the regulatory authorities. CPV
documentation will likely form the basis for
your APR reports, but that is not their primary
objective. Your CPV Program should reflect
this internal focus.
Slide 45
Company Confidential
46. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Considerations for Implementation
Raw Materials & Components:
• Are existing specifications adequate for ensuring tight control of
material quality going into the process?
• Even if adequate specifications are in place, have we reviewed
historical material quality to see what kind of variability we have
within the defined specifications and whether or not such variability
has the potential to impact product quality?
• Have component material of construction compatibility and
leachables/extractables studies adequately ensured low risk to
product quality? If not, is there additional testing that can be done
as part of CPV to mitigate risk?
Slide 46
Company Confidential
47. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Considerations for Implementation
In-Process Data:
The PPQ Protocols and Reports are a good starting point for the in-
process data section of the CPV plan since (in theory) a company has
already “funneled” all process parameters through risk assessment
and, if needed, characterization (again, leveraging Stage 1 & 2
information to inform Stage 3). In addition, the PPQ protocols will have
identified any additional sampling/testing required for validation and
those should also be considered for Stage 3.
Slide 47
Company Confidential
48. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Considerations for Implementation
In-Process Data:
• Is this parameter subject to normal distribution and
trending?
• Did we gain a sufficient statistical confidence in our
process during PPQ to drop any additional testing?
• If we didn’t gain statistical confidence from our additional
testing during PPQ, then how many more batches will it
take to do so?
Slide 48
Company Confidential
49. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Considerations for Implementation
Release Data:
• This one usually isn’t as much of a problem,
because data compilation and communication
are required for lot release.
• However, just as some in-process data are
subject to statistical trending and others are not,
so it is the same with release data. Such
distinctions should be identified in the CPV Plan.
Slide 49
Company Confidential
50. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
What Would Output Look Like?
Slide 50
Company Confidential
Critical Operating Parameter Normal Operating Range CPV Strategy
Carbon feed rate Target ± 15%
Not subject to SPC; however, important to monitor controller
variability, so will plot glucose feed profile for comparison
(overlay) with previous batches
In-Process Control Limit(s) CPV Strategy
DO ≥ 10%
Not subject to SPC; characterization data shows that any value
above 10% is sufficient for consistent fermentation
performance; no routine trending required, but any IPC failure
will be fully investigated for impact to the validated state
Total Acid Addition Volume ≤ 6.0 kg
Known to have direct impact on product quality and subject to
SPC; parameter will be control charted
In-Process Acceptance Criterion Acceptance Criterion CPV Strategy
Final Wet Cell Weight > 250 g/L
Important indicator of process consistency and subject to SPC;
parameter will be control charted
Culture Purity (Plating Method) No Contaminating Organisms
Not subject to SPC; existing quality systems would ensure that
a failure would result in batch termination.
Final Product Titer ≥ 3.0 g/L
Important indicator of process consistency and subject to SPC;
parameter will be control charted
Additional Testing Acceptance Criterion CPV Strategy
Antifoam Concentration Report Value
This result is used as a baseline value for assessing antifoam
clearance further downstream; PPQ batches demonstrate tight
control of antifoam clearance to < LOQ, so testing will be
discontinued.
51. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Considerations for Implementation
Events-Based Data/Information:
• Are the appropriate systems in place to thoroughly
assess events-based issues like deviations, OOS
results, operator observations, change control, adverse
events, etc.?
• If they are already in place, then the project team should
be focused on ensuring that all of those various pieces
of information are being fed back into a CPV system that
ensures timely communication of process/product risk
across the organization.
Slide 51
Company Confidential
52. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
CPV Reporting Mechanisms
• The types of data/information that will be formally
assessed via CPV should be defined by a cross-
functional team and documented by way of a CPV Plan.
• Regardless of the product type, it should be clear that
process data/information are being evaluated on a
continual basis and that outcomes are being formally
documented and communicated across the organization
on a more frequent than annual basis.
Slide 52
Company Confidential
53. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Considerations for Legacy Products
• In some ways, legacy products have an advantage in
that there is an existing historical data set that should be
conducive for establishing SPC limits.
• So, walk through the same CPV exercise that we just
discussed:
– Identify any high risk raw materials and components and take
appropriate mitigating actions.
– Review Process Control Strategy and determine which data are
subject to trending and which are not.
– Review quality systems and determine which events-based data
will be compiled and reported as part of CPV
– Develop a CPV Plan to ensure timely reporting and
communicating CPV data/information across the organization.
Slide 53
Company Confidential
54. TECH
LOGICBIO TECH
LOGICBIO ®BioTechLogic, Inc.
Conclusion
Don’t default to assessing and reporting everything about
your process in Stage 3. Instead, utilize the risk-based and
science-based “filters” established during Stage 1 and 2
and rely on existing quality systems to ensure that the right
set of data are being monitored, and then ensure that a
system is in place to communicate that information across
the organization.
Slide 54
Company Confidential